BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

News & Events

BD First Quarter Results Fiscal Year 2016 Financial Presentation

BD Announces Results for 2016 First Fiscal Quarter

BD Board Declares Dividend

BD Announces Webcast of Annual Meeting of Shareholders

Fresenius Kabi USA Acquires U.S. Pharmaceutical Plant and Ready to Administer Drugs from BD

BD Divests BD RX Business, Adding IV Solutions

BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call

BD to Present at the 34th Annual J. P. Morgan Healthcare Conference

BD Unveils New BD FACSCelesta™ Flow Cytometer During the 2015 American Society for Cell Biology Annual Meeting

CareFusion Receives Two 510(K) Clearances for Spine Products

BD Introduces Simplified Comprehensive IV Management

BD Showcases Expanded Portfolio to Support Enterprise Medication Management at the ASHP 2015 Midyear Meeting

BD Board Declares Dividend

BD Named Global Company of the Year for Clinical and Research Flow Cytometry by Frost & Sullivan

BD Announces Results for 2015 Fourth Fiscal Quarter and Full Year

BD Launches the BD FACSseq™ Cell Sorter with BD™ Precise Assays for High Precision Single Cell Genomics

BD Life Sciences to Sponsor with Johns Hopkins University's Prestigious Business Accelerator Program, FastForward

BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call

BD Third Quarter Results Fiscal Year 2015 Financial Presentation

BD Announces Results for 2015 Third Fiscal Quarter

BD Board Declares Dividend

BD Announces Sustainability Goals for 2020

BD and Medtronic Collaborate to Introduce a New Infusion Set with BD FlowSmart™ Technology Designed to Improve Insulin Pump Therapy

New Clinical Data Suggest Infusion Set with BD FlowSmart™ Technology May Improve Insulin Flow and Reduce Silent Occlusions

BD Receives FDA Clearance for a Novel Infusion Set with BD FlowSmart™ Technology to Enhance the Use of Insulin Pumps

BD "Dynamic Duos" Education Campaign Aims to Help People Simplify Life with Diabetes

BD Obtains CE Mark for CT/GC/TV and CT/GC Assays on the BD MAX™ System

Presentation: BD Completes Acquisition of CareFusion

Becton Dickinson Completes Acquisition of CareFusion

European Commission Clears BD Acquisition of CareFusion

BD Acquires CRISI Medical Systems

BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing

The BD™ Intelliport® Medication Management System Receives Clearance from the Food and Drug Administration (FDA)

Becton Dickinson and CareFusion Announce Expiration of HSR Act Waiting Period in Proposed Transaction

BD to Acquire CareFusion


carefusion joins bd pdf
Annual Report
AdvaMed Life Changing Innovation
Sustainability Report 2014